Albumin Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
Growth Factors of Albumin Market
The albumin market size was valued at USD 6.35 billion in 2023, and the market is now projected to grow from USD 6.57 billion in 2024 to USD 10.19 billion by 2032, exhibiting a CAGR of 5.6% during the forecast period of 2024-2032.
The COVID-19 pandemic created significant opportunities on the albumin market growth as curbing coronavirus outbreak was prioritized. The spread of the Coronavirus pandemic emphatically affected the development of the worldwide albumin market. The development was essentially ascribed to the rising innovative work drives to demonstrate the impacts of this item on Coronavirus positive patients. In any case, in 2021, the market experienced sluggish development because of breaks in plasma assortment in the earlier year. By and by, in 2022 and 2023, the market experienced hearty development because of a superior stock of plasma and new item dispatches on the lookout.
The albumin market share globally has been contributed due to the Expanded Commonness of Hypoalbuminemia. There has been a significant development in the interest for plasma-derived treatments, particularly albumin, across the world. This development is chiefly ascribed to the ascent in the instances of different perilous problems, extraordinary liver illnesses, diseases, and heart medical procedures, prompting hypoalbuminemia. Hypoalbuminemia is a condition that results in the diminished creation of albumin or expanded loss of this protein by means of the kidneys, gastrointestinal (GI) tract, skin, or extravascular space. It is the most transcendent problem in the fundamentally sick and hospitalized patients. Such dangerous problems can be treated with albumin therapeutics or through unambiguous albumin treatments. Subsequently, the developing prerequisite for such medicines is projected to drive the interest for albumin-based treatments.
Furthermore, there’s been a notable trend of Presence of Recombinant Albumin. Albumin is seeing tremendous interest in human therapeutics for reestablishing blood volume and supplanting lost liquids during mishaps, serious consume wounds, fetal erythroblastosis, hypoproteinemia, and medical procedures. Recombinant albumin offers broad advantages over human or creature level serum items concerning higher virtue, nonattendance of creature material, and higher homogeneity. Also, recombinant human serum items are hydrophobic, which offers them a phenomenal ability to convey different ligands. This has expanded their interest in drug conveyance applications. Besides, noticeable players in the worldwide market are centered around a few development systems, for example, consolidations and organizations to reinforce their item portfolio to foster high level treatments.
Comprehensive Albumin Market
Albumin is the most plentiful coursing protein tracked down in plasma. It is integrated by the liver and vital for managing the osmotic tension of the blood. Factors, for example, expanded commonness of hypoalbuminemia and other ailments, ascend in plasma fractionation offices, and flood in plasma assortment is driving the worldwide albumin market development. Research exercises that decide albumin' viability are picking up speed universally. Researchers have distributed a few examinations concentrates on in different diaries enrolling treatment choices for various circumstances. Likewise, developments by conspicuous players on the lookout and a flood in the quantity of item endorsements will introduce valuable learning experiences for the worldwide market before long.
Asia Pacific represented the most noteworthy offer in this market. The locale was esteemed at USD 3.42 billion of every 2023. China is the world's biggest human albumin market as there is a critical interest for these items. The territorial market's development is described by the extension of assembling units in China, developing interests in Research and development, and strong reception of helpful items.
The top players in the market play a crucial role in the albumin market assuring industrial prospectus growth and setting market standards. These players include, CSL Behring (CSL), (U.S.), Kedrion S.p.A. (Italy), Takeda Pharmaceutical Company Limited (Japan), Lazuline Bio (India), InVitria (U.S.) these market players provide a level-playing competitive landscape.
In August 2023, Dyadic International, Inc., a biotechnology organization, reported positive outcomes from the outsider scientific testing of its without creature recombinant serum albumin.
Segmentation Table
Albumin Market Scope
Study Period 2019-2032
Base Year 2023
Forecast Period 2024-2032
Growth Rate CAGR of 5.6% from 2024-2032
Historical Period 2019-2022
Unit Value (USD Billion)
Segmentation By Type, End-User, and Region
By Type Human Serum Albumin
Recombinant Albumin
Bovine Serum Albumin
By End-User
Therapeutics
Diagnostics
Research
By Region North America (By Type, End-User, and Country)
- U.S. (By Type and End-User)
- Canada (By Type and End-User)
Europe (By Type, End-User, and Country/Sub-region)
- U.K. (By Type and End-User)
- Germany (By Type and End-User)
- France (By Type and End-User)
- Italy (By Type and End-User)
- Spain (By Type and End-User)
- Rest of Europe (By Type and End-User)
Asia Pacific (By Type, End-User, and Country/Sub-region)
- China (By Type and End-User)
- Japan (By Type and End-User)
- India (By Type and End-User)
- Australia (By Type and End-User)
- Rest of Asia Pacific (By Type and End-User)
Latin America (By Type, End-User, and Country/Sub-region)
- Brazil (By Type and End-User)
- Mexico (By Type and End-User)
- Rest of Latin America (By Type and End-User)
Middle East & Africa (By Type, End-User, and Country/ Sub-region)
- GCC (By Type and End-User)
- South Africa (By Type and End-User)
- Rest of Middle East & Africa (By Type and End-User)
Please Note: It will take 5-6 business days to complete the report upon order confirmation.
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 4. Key Insights
- 4.1. Prevalence of Related Disorders: By Key Countries
- 4.2. Overview: rHSA Product Parameters
- 4.3. New Product Launches, By Key Players
- 4.4. Pipeline Analysis, By Key Players
- 4.5. Overview: Trends in Albumin Market
- 4.6. Key Industry Developments (Mergers, Acquisitions and Partnerships)
- 4.7. Impact of COVID-19 on the Market
- 5. Global Albumin Market Analysis, Insights and Forecast, 2019-2032
- 5.1. Market Analysis, Insights and Forecast – By Product
- 5.1.1. Human Serum Albumin
- 5.1.2. Recombinant Albumin
- 5.1.3. Bovine Serum Albumin
- 5.2. Market Analysis, Insights and Forecast – By Application
- 5.2.1. Therapeutics
- 5.2.2. Diagnostics
- 5.2.3. Research
- 5.3. Market Analysis, Insights and Forecast – By End-user
- 5.3.1. Hospital & Clinics
- 5.3.2. Pharmaceutical & Biotechnology Industry
- 5.3.3. Research Institutes
- 5.4. Market Analysis, Insights and Forecast – By Region
- 5.4.1. North America
- 5.4.2. Europe
- 5.4.3. Asia Pacific
- 5.4.4. Latin America
- 5.4.5. Middle East & Africa
- 6. North America Albumin Market Analysis, Insights and Forecast, 2019-2032
- 6.1. Market Analysis, Insights and Forecast – By Product
- 6.1.1. Human Serum Albumin
- 6.1.2. Recombinant Albumin
- 6.1.3. Bovine Serum Albumin
- 6.2. Market Analysis, Insights and Forecast – By Application
- 6.2.1. Therapeutics
- 6.2.2. Diagnostics
- 6.2.3. Research
- 6.3. Market Analysis, Insights and Forecast – By End-user
- 6.3.1. Hospital & Clinics
- 6.3.2. Pharmaceutical & Biotechnology Industry
- 6.3.3. Research Institutes
- 6.4. Market Analysis – By Country
- 6.4.1. U.S.
- 6.4.2. Canada
- 7. Europe Albumin Market Analysis, Insights and Forecast, 2019-2032
- 7.1. Market Analysis, Insights and Forecast – By Product
- 7.1.1. Human Serum Albumin
- 7.1.2. Recombinant Albumin
- 7.1.3. Bovine Serum Albumin
- 7.2. Market Analysis, Insights and Forecast – By Application
- 7.2.1. Therapeutics
- 7.2.2. Diagnostics
- 7.2.3. Research
- 7.3. Market Analysis, Insights and Forecast – By End-user
- 7.3.1. Hospital & Clinics
- 7.3.2. Pharmaceutical & Biotechnology Industry
- 7.3.3. Research Institutes
- 7.4. Market Analysis – By Country/ Sub-Region
- 7.4.1. U.K.
- 7.4.2. Germany
- 7.4.3. France
- 7.4.4. Spain
- 7.4.5. Italy
- 7.4.6. Scandinavia
- 7.4.7. Rest of Europe
- 8. Asia Pacific Albumin Market Analysis, Insights and Forecast, 2019-2032
- 8.1. Market Analysis, Insights and Forecast – By Product
- 8.1.1. Human Serum Albumin
- 8.1.2. Recombinant Albumin
- 8.1.3. Bovine Serum Albumin
- 8.2. Market Analysis, Insights and Forecast – By Application
- 8.2.1. Therapeutics
- 8.2.2. Diagnostics
- 8.2.3. Research
- 8.3. Market Analysis, Insights and Forecast – By End-user
- 8.3.1. Hospital & Clinics
- 8.3.2. Pharmaceutical & Biotechnology Industry
- 8.3.3. Research Institutes
- 8.4. Market Analysis – By Country/ Sub-Region
- 8.4.1. Japan
- 8.4.2. China
- 8.4.3. India
- 8.4.4. Australia
- 8.4.5. Southeast Asia
- 8.4.6. Rest of Asia Pacific
- 9. Latin America Albumin Market Analysis, Insights and Forecast, 2019-2032
- 9.1. Market Analysis, Insights and Forecast – By Product
- 9.1.1. Human Serum Albumin
- 9.1.2. Recombinant Albumin
- 9.1.3. Bovine Serum Albumin
- 9.2. Market Analysis, Insights and Forecast – By Application
- 9.2.1. Therapeutics
- 9.2.2. Diagnostics
- 9.2.3. Research
- 9.3. Market Analysis, Insights and Forecast – By End-user
- 9.3.1. Hospital & Clinics
- 9.3.2. Pharmaceutical & Biotechnology Industry
- 9.3.3. Research Institutes
- 9.4. Market Analysis – By Country/ Sub-Region
- 9.4.1. Brazil
- 9.4.2. Mexico
- 9.4.3. Rest of Latin America
- 10. Middle East & Africa Albumin Market Analysis, Insights and Forecast, 2019-2032
- 10.1. Market Analysis, Insights and Forecast – By Product
- 10.1.1. Human Serum Albumin
- 10.1.2. Recombinant Albumin
- 10.1.3. Bovine Serum Albumin
- 10.2. Market Analysis, Insights and Forecast – By Application
- 10.2.1. Therapeutics
- 10.2.2. Diagnostics
- 10.2.3. Research
- 10.3. Market Analysis, Insights and Forecast – By End-user
- 10.3.1. Hospital & Clinics
- 10.3.2. Pharmaceutical & Biotechnology Industry
- 10.3.3. Research Institutes
- 10.4. Market Analysis – By Country/ Sub-Region
- 10.4.1. GCC Countries
- 10.4.2. South Africa
- 10.4.3. Rest of Middle East & Africa
- 11. Competitive Analysis
- 11.1. Global Market Share Analysis (2023)
- 11.2. Company Profiles
- 11.2.1. CSL Behring (CSL)
- 11.2.1.1. Overview
- 11.2.1.2. Products
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Strategies
- 11.2.1.6. Financials (Based On Availability)
- 11.2.2. Kedrion S.p.A.
- 11.2.2.1. Overview
- 11.2.2.2. Products
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Strategies
- 11.2.2.6. Financials (Based On Availability)
- 11.2.3. Takeda Pharmaceutical Company Limited
- 11.2.3.1. Overview
- 11.2.3.2. Products
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Strategies
- 11.2.3.6. Financials (Based On Availability)
- 11.2.4. Lazuline Bio
- 11.2.4.1. Overview
- 11.2.4.2. Products
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Strategies
- 11.2.4.6. Financials (Based On Availability)
- 11.2.5. InVitria
- 11.2.5.1. Overview
- 11.2.5.2. Products
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Strategies
- 11.2.5.6. Financials (Based On Availability)
- 11.2.6. Biorbyt Ltd.
- 11.2.6.1. Overview
- 11.2.6.2. Products
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Strategies
- 11.2.6.6. Financials (Based On Availability)
- 11.2.7. Grifols, S.A.
- 11.2.7.1. Overview
- 11.2.7.2. Products
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Strategies
- 11.2.7.6. Financials (Based On Availability)
- 11.2.8. Octapharma AG
- 11.2.8.1. Overview
- 11.2.8.2. Products
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Strategies
- 11.2.8.6. Financials (Based On Availability)
- 11.2.9. Albumin Bioscience
- 11.2.9.1. Overview
- 11.2.9.2. Products
- 11.2.9.3. SWOT Analysis
- 11.2.9.4. Recent Developments
- 11.2.9.5. Strategies
- 11.2.9.6. Financials (Based On Availability)
- 11.2.10. Aspira Chemical
- 11.2.10.1. Overview
- 11.2.10.2. Products
- 11.2.10.3. SWOT Analysis
- 11.2.10.4. Recent Developments
- 11.2.10.5. Strategies
- 11.2.10.6. Financials (Based On Availability)
- 11.2.11. ALBUMEDIX (Sartorius AG)
- 11.2.11.1. Overview
- 11.2.11.2. Products
- 11.2.11.3. SWOT Analysis
- 11.2.11.4. Recent Developments
- 11.2.11.5. Strategies
- 11.2.11.6. Financials (Based On Availability)
- 11.2.12. Cyagen Biosciences
- 11.2.12.1. Overview
- 11.2.12.2. Products
- 11.2.12.3. SWOT Analysis
- 11.2.12.4. Recent Developments
- 11.2.12.5. Strategies
- 11.2.12.6. Financials (Based On Availability)
- 11.2.13. Merck KGaA
- 11.2.13.1. Overview
- 11.2.13.2. Products
- 11.2.13.3. SWOT Analysis
- 11.2.13.4. Recent Developments
- 11.2.13.5. Strategies
- 11.2.13.6. Financials (Based On Availability)
- 11.2.14. Thermo Fisher Scientific Inc.
- 11.2.14.1. Overview
- 11.2.14.2. Products
- 11.2.14.3. SWOT Analysis
- 11.2.14.4. Recent Developments
- 11.2.14.5. Strategies
- 11.2.14.6. Financials (Based On Availability)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook